Evolus, Inc. Files 2024 10-K

Ticker: EOLS · Form: 10-K · Filed: Mar 4, 2025 · CIK: 1570562

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

TL;DR

Evolus filed its 2024 10-K. Full financials inside.

AI Summary

Evolus, Inc. filed its 2024 10-K on March 4, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Newport Beach, CA, operates in the pharmaceutical preparations sector. The filing covers financial performance and business operations for the period, with specific financial data to be detailed within the full report.

Why It Matters

This 10-K filing provides a comprehensive overview of Evolus, Inc.'s financial health and strategic direction for the 2024 fiscal year, crucial for investors and stakeholders to assess the company's performance and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Evolus faces inherent risks related to product development, regulatory approvals, market competition, and intellectual property, which are typically detailed in a 10-K filing.

Key Numbers

Key Players & Entities

FAQ

What were Evolus, Inc.'s total revenues for the fiscal year ended December 31, 2024?

The provided text does not contain specific revenue figures for the fiscal year ended December 31, 2024. The full 10-K document would detail this information.

What is Evolus, Inc.'s primary business segment?

Evolus, Inc. operates within the Pharmaceutical Preparations sector, as indicated by its SIC code 2834.

When was this 10-K filing submitted to the SEC?

This 10-K filing was submitted to the SEC on March 4, 2025.

Where is Evolus, Inc. headquartered?

Evolus, Inc. is headquartered in Newport Beach, CA, with its business and mailing address listed as 520 Newport Center Drive, Suite 1200.

What is the SEC file number for Evolus, Inc.'s 10-K filing?

The SEC file number for this 10-K filing is 001-38381.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 4, 2025 regarding Evolus, Inc. (EOLS).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing